Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactobacillus reuteri for peri-implant biofilm and inflammation
DRKS00030602Phase 4Completed
- Sponsor
- Clinic of Conservative and Preventive Dentistry, University of Zurich
- Start
- Oct 2022
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of lactobacillus reuteri in edentulism, peri-implant mucositis, dental biofilm and 1 more (2 arms), sponsored by Clinic of Conservative and Preventive Dentistry, University of Zurich. Primary endpoints: Subgingival biofilm formation on healing abutments and Inflammatory status of peri-implant tissues. Started Oct 2022; status: completed.
02
Drugs
lactobacillus reuteri
03
Conditions
edentulismperi-implant mucositisdental biofilmperi-implant disease
Beyond the preview
Go deeper on DRKS00030602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00030602.